Xeris gets $41M for shelf-stable glucagon pen
The company's using the funding to help commercialize its shelf-stable glucagon pen for hypoglycemia in diabetics.
The company's using the funding to help commercialize its shelf-stable glucagon pen for hypoglycemia in diabetics.